Comprehensive Stock Comparison
Compare Virax Biolabs Group Limited (VRAX) vs Veracyte, Inc. (VCYT) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  VCYT | 16.0% revenue growth vs VRAX's -96.0% |
| Quality / Margins | VCYT | 12.8% net margin vs VRAX's -78.6% |
| Stability / Safety | VCYT | Beta 1.12 vs VRAX's 1.24, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | VCYT | +10.0% vs VRAX's -84.6% |
| Efficiency (ROA) | VCYT | 4.7% ROA vs VRAX's -199.1%, ROIC 4.4% vs -273.2% |
Who Each Stock Is For
Income & stability
VCYTbeta 1.12
Growth exposure
VCYTRev growth 16.0%, EPS growth 164.5%, 3Y rev CAGR 20.4%
Long-term compounding (10Y)
VCYT443.8% 10Y total return vs VRAX's -99.9%
Sleep-well-at-night portfolio
VCYTLower volatility, beta 1.12, Low D/E 3.0%, current ratio 8.15x
Defensive / Recession hedge
VCYTBeta 1.12, current ratio 8.15x
Business Model
What each company does and how it makes money
Virax Biolabs Group is a biotechnology company focused on viral disease prevention, detection, and management through diagnostic test kits and medical technology products. It generates revenue primarily from selling diagnostic tests—including rapid antibody, antigen, and PCR tests under the ViraxClear brand—and medical/PPE products under the ViraxCare brand, distributed through clinics, pharmacies, hospitals, and an online platform. The company's competitive advantage lies in its integrated portfolio spanning diagnostics and protective equipment for viral diseases, serving both healthcare institutions and corporate clients across multiple international markets.
Veracyte is a molecular diagnostics company that develops genomic tests to improve cancer and other disease diagnosis and treatment decisions. It generates revenue primarily from diagnostic test sales — including its Afirma thyroid, Decipher prostate, and Percepta lung cancer tests — with additional income from technology licensing partnerships. The company's competitive advantage lies in its proprietary genomic classifiers and biobank of clinical samples that enable development of clinically validated tests with strong physician adoption.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
VCYT 4
VRAX 1VCYT6/6 metricsVRAX2/3 metricsVCYT7/8 metricsVCYT6/6 metricsVCYT2/2 metricsVCYT leads in 4 of 6 categories (Financial Metrics, Profitability & Efficiency). VRAX leads in 1 (Valuation Metrics).
Financial Metrics (TTM)
VCYT is the larger business by revenue, generating $517M annually — 3177.5x VRAX's $162,750. VCYT is the more profitable business, keeping 12.8% of every revenue dollar as net income compared to VRAX's -78.6%. On growth, VCYT holds the edge at +18.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | VRAXVirax Biolabs Gro… | VCYTVeracyte, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $162,750 | $517M |
| EBITDAEarnings before interest/tax | -$12M | $74M |
| Net IncomeAfter-tax profit | -$13M | $66M |
| Free Cash FlowCash after capex | -$13M | $126M |
| Gross MarginGross profit ÷ Revenue | -1.5% | +70.1% |
| Operating MarginEBIT ÷ Revenue | -77.8% | +11.2% |
| Net MarginNet income ÷ Revenue | -78.6% | +12.8% |
| FCF MarginFCF ÷ Revenue | -77.3% | +24.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | -98.3% | +18.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +55.6% | +7.3% |
Valuation Metrics
| Metric | VRAXVirax Biolabs Gro… | VCYTVeracyte, Inc. |
|---|---|---|
| Market CapShares × price | $2M | $2.9B |
| Enterprise ValueMkt cap + debt − cash | -$2M | $2.6B |
| Trailing P/EPrice ÷ TTM EPS | -0.11x | 44.23x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 22.03x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 44.23x |
| Price / SalesMarket cap ÷ Revenue | 245.06x | 5.57x |
| Price / BookPrice ÷ Book value/share | 0.12x | 2.23x |
| Price / FCFMarket cap ÷ FCF | — | 22.73x |
Profitability & Efficiency
VCYT delivers a 5.1% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $-2 for VRAX. VCYT carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to VRAX's 0.07x. On the Piotroski fundamental quality scale (0–9), VCYT scores 8/9 vs VRAX's 1/9, reflecting strong financial health.
| Metric | VRAXVirax Biolabs Gro… | VCYTVeracyte, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -2.3% | +5.1% |
| ROA (TTM)Return on assets | -199.1% | +4.7% |
| ROICReturn on invested capital | -2.7% | +4.4% |
| ROCEReturn on capital employed | -111.4% | +4.5% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 8 |
| Debt / EquityFinancial leverage | 0.07x | 0.03x |
| Net DebtTotal debt minus cash | -$4M | -$323M |
| Cash & Equiv.Liquid assets | $4M | $363M |
| Total DebtShort + long-term debt | $377,004 | $40M |
| Interest CoverageEBIT ÷ Interest expense | -149.04x | — |
Total Returns (with DRIP)
A $10,000 investment in VCYT five years ago would be worth $7,634 today (with dividends reinvested), compared to $11 for VRAX. Over the past 12 months, VCYT leads with a +10.0% total return vs VRAX's -84.6%. The 3-year compound annual growth rate (CAGR) favors VCYT at 15.2% vs VRAX's -68.4% — a key indicator of consistent wealth creation.
| Metric | VRAXVirax Biolabs Gro… | VCYTVeracyte, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -45.6% | -14.4% |
| 1-Year ReturnPast 12 months | -84.6% | +10.0% |
| 3-Year ReturnCumulative with dividends | -96.8% | +52.8% |
| 5-Year ReturnCumulative with dividends | -99.9% | -23.7% |
| 10-Year ReturnCumulative with dividends | -99.9% | +443.8% |
| CAGR (3Y)Annualised 3-year return | -68.4% | +15.2% |
Risk & Volatility
VCYT is the less volatile stock with a 1.12 beta — it tends to amplify market swings less than VRAX's 1.24 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VCYT currently trades 71.5% from its 52-week high vs VRAX's 13.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VRAXVirax Biolabs Gro… | VCYTVeracyte, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.24x | 1.12x |
| 52-Week HighHighest price in past year | $1.58 | $50.71 |
| 52-Week LowLowest price in past year | $0.19 | $22.61 |
| % of 52W HighCurrent price vs 52-week peak | +13.2% | +71.5% |
| RSI (14)Momentum oscillator 0–100 | 37.3 | 39.9 |
| Avg Volume (50D)Average daily shares traded | 320K | 807K |
Analyst Outlook
| Metric | VRAXVirax Biolabs Gro… | VCYTVeracyte, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $47.25 |
| # AnalystsCovering analysts | — | 20 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jul 22 | Mar 26 | Change |
|---|---|---|---|
| Virax Biolabs Group… (VRAX) | 100 | 0.12 | -99.9% |
| Veracyte, Inc. (VCYT) | 100 | 139.47 | +39.5% |
Veracyte, Inc. (VCYT) returned -24% over 5 years vs Virax Biolabs Group… (VRAX)'s -100%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Virax Biolabs Group… (VRAX) | $99876.00 | $6331.00 | -93.7% |
| Veracyte, Inc. (VCYT) | $65M | $517M | +694.6% |
Veracyte, Inc.'s revenue grew from $65M (2016) to $517M (2025) — a 25.9% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Virax Biolabs Group… (VRAX) | -8.0% | -957.4% | -11835.7% |
| Veracyte, Inc. (VCYT) | -48.2% | 12.8% | +126.6% |
Veracyte, Inc.'s net margin went from -48% (2016) to 13% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Virax Biolabs Group… (VRAX) | -0.7 | -1.95 | -178.6% |
| Veracyte, Inc. (VCYT) | -1.09 | 0.82 | +175.2% |
Veracyte, Inc.'s EPS grew from $-1.09 (2016) to $0.82 (2025).
Chart 5Free Cash Flow — 5 Years
Virax Biolabs Group Limited generated $-5M FCF in 2025 (-776% vs 2021). Veracyte, Inc. generated $127M FCF in 2025 (+442% vs 2021).
VRAX vs VCYT: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is VRAX or VCYT a better buy right now?
Veracyte, Inc. (VCYT) offers the better valuation at 44.2x trailing P/E (22.0x forward), making it the more compelling value choice. Analysts rate Veracyte, Inc. (VCYT) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VRAX or VCYT?
Over the past 5 years, Veracyte, Inc. (VCYT) delivered a total return of -23.7%, compared to -99.9% for Virax Biolabs Group Limited (VRAX). A $10,000 investment in VCYT five years ago would be worth approximately $8K today (assuming dividends reinvested). Over 10 years, the gap is even starker: VCYT returned +443.8% versus VRAX's -99.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VRAX or VCYT?
By beta (market sensitivity over 5 years), Veracyte, Inc. (VCYT) is the lower-risk stock at 1.12β versus Virax Biolabs Group Limited's 1.24β — meaning VRAX is approximately 11% more volatile than VCYT relative to the S&P 500. On balance sheet safety, Veracyte, Inc. (VCYT) carries a lower debt/equity ratio of 3% versus 7% for Virax Biolabs Group Limited — giving it more financial flexibility in a downturn.
04Which has better profit margins — VRAX or VCYT?
Veracyte, Inc. (VCYT) is the more profitable company, earning 12.8% net margin versus -957.4% for Virax Biolabs Group Limited — meaning it keeps 12.8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VCYT leads at 11.2% versus -973.4% for VRAX. At the gross margin level — before operating expenses — VCYT leads at 70.1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — VRAX or VCYT?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is VRAX or VCYT better for a retirement portfolio?
For long-horizon retirement investors, Veracyte, Inc. (VCYT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.12), +443.8% 10Y return). Both have compounded well over 10 years (VCYT: +443.8%, VRAX: -99.9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between VRAX and VCYT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.